We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Europe Allows Sale of Genetically Modified Corn

By Biotechdaily staff writers
Posted on 25 May 2004
Despite reservations on the part of many of the member states, the European Commission has announced it will allow the sale of Bt-11 sweet corn, thereby ending a six-year moratorium on the import of genetically modified (GM) food products. More...
The ruling will allow the import of Bt-11 corn already canned and ready for the supermarket shelf. Members of the European Union (EU) will not be allowed to cultivate Bt-11 sweet corn.

Bt-11 sweet corn was developed by Syngenta (Basel, Switzerland). Normal maize (Zea mays) was modified by the insertion of a gene from the bacterium Bacillus thuringiensis that produces the Bt protein Cry1Ab. When eaten by the European corn borer or corn earworm, two important sweet corn pests, digestive enzymes in the alkaline environment of the larva's intestine metabolize Cry1Ab, yielding a shorter protein that binds to the wall of the intestine. Following binding, pores are formed that disrupt midgut ion flow, causing gut paralysis and eventual death from bacterial sepsis. Cry1Ab is lethal only when eaten by the larvae of lepidopteran insects (moths and butterflies), and its specificity of action is directly attributable to the presence of specific binding sites in the target insects. There are no binding sites for the delta-endotoxins of B thuringiensis on the surface of mammalian intestinal cells. Therefore, livestock animals and humans are not susceptible to these proteins.

The safety of Bt-11 sweet corn for use as a food has been demonstrated by digestibility studies, toxicity studies, and allergenicity studies. The composition and nutritional value of Bt-11 has been shown to be comparable or substantially equivalent to non-Bt sweet corn. Objection to the use of GM corn is based primarily on anecdotal reports such as those of livestock dying of "mysterious” illnesses after having been fed genetically modified maize. Other concerns center on the genetic stability of the modified plants and on the activity of the Bt genes as they move up the food chain.

While the World Health Organization (WHO, Geneva, Switzerland) is strongly promoting GM foods as the key to preventing food shortages in the coming decades, the success of GM foods in Europe will largely be determined by the willingness of consumers to buy them.




Related Links:
Syngenta

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.